Ann: Trading Halt, page-44

kind of between me and him but in general it was just about how him and the rest of the board are bullish in this stock, comparing it to other biomeds and saying the corporate overhead is one of the lowest going around for a company in phase 3. That they arent here to gouge large cash salaries that they want to make this drug successful etc etc

Just reaffirming that they arent in it as a lifestyle company and the hunger they have more than anything. This is the type of management I love to see in spec companies because its what drives success. Management of cashflow, hunger for success, looking for the best deals to benefit shareholders. I think we are in good hands and happy with where its going, all IMO though.

Still a while to go, but if you were to get a buyout deal at $8-$10 for example in 3 years time, I think that's a pretty decent investment. 20 bag plus from here over 3 years, why not hey (again all speculation DYOR)